6533b7dafe1ef96bd126e2ab

RESEARCH PRODUCT

Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus.

C. IntriviciNicola GebbiaF AragonaAntonio RussoValentina AgneseDaniela CabibiGianni PantusoEugenio FiorentinoDonatella CalcaraMarianna TerrasiV. BazanGiuseppe Colucci

subject

AdultMalemedicine.medical_specialtyPathologyEsophageal NeoplasmsSettore MED/06 - Oncologia MedicaAneuploidySettore BIO/11 - Biologia MolecolareAdenocarcinomaProtein Serine-Threonine KinasesSettore MED/08 - Anatomia PatologicaGastroenterologyBarrett EsophagusAurora KinasesInternal medicineBiopsymedicineHumansAurora-A overexpression Barrett’s oesophagus cell cycle columnar-lined oesophagus p53 proteinProspective StudiesEsophagusMucous Membranemedicine.diagnostic_testEsophageal diseasebusiness.industryIntestinal metaplasiaHematologyMiddle Agedmedicine.diseasemedicine.anatomical_structureOncologyDysplasiaBarrett's esophagusGastroesophageal RefluxFemalebusinessImmunostainingBiomarkers

description

Abstract BACKGROUND: The development of oesophageal adenocarcinoma is generally closely associated with the presence of a specialised intestinal-type epithelium such as that found in Barrett's oesophagus (BO). A particular histological condition is when the distal oesophagus showing cardiac and/or fundic mucosa without intestinal metaplasia cannot be defined as 'Barrett's mucosa' [condition that we call 'columnar-lined oesophagus' (CLO)] and up till now, there has been no agreement in literature about the management of this condition. Aurora-A overexpression leads to centrosome amplification, chromosomal instability and aneuploidy in mammalian cells. PATIENTS AND METHODS: A prospective study was carried out on 28 consecutive patients who presented columnar mucosa above the gastro-oesophageal junction (GOJ) at endoscopy. As controls, two more biopsies were obtained, one on the normal-appearing squamous oesophagus above the GOJ, as far as possible from the columnar mucosa (controls A), and one taken 1 cm below the GOJ (controls B). The Aurora-A and p53 expression levels were analysed respectively by Quantitative Real Time PCR and immunohistochemistry. RESULTS: Twelve patients were affected by BO (43%) while the other 16 patients (57%) had a CLO. Nine of 28 (32%) cases were focally positive for p53 immunostaining. All the BO/CLO samples were positive for the Aurora-A transcript with regard to controls. Furthermore, 13 of 28 (46%) cases showed overexpression (above the median for the whole group). CONCLUSION: Due to the low number of cases, we are not at present able to state that statistically significant quantitative differences in Aurora-A messenger RNA expression exist between CLO and BO cases with and without dysplasia and p53-positive immunostaining. Further studies on a larger number of cases with a follow-up period are necessary in order to establish the risk of progression and the correct management of these subjects.

10.1093/annonc/mdm237http://hdl.handle.net/10447/23565